3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
6
Myelodysplastic Syndromes
4
Primary Myelofibrosis
2
Myeloproliferative Disorders
2
Thrombocythemia, Essential
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasm Metastasis
1
Melanoma
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia
1
Carcinoma, Squamous Cell
1
Interventions
venetoclax
1
prednylidene
1
navitoclax
1
deltacortene
1
Vincristine
1
Rituximab
1
Prednisone
1
Leyk
1
Imatinib Mesylate
1
Etoposide
1
Doxorubicin
1
Decitabine
1
Cyclophosphamide
1
Asparaginase
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
×
Decitabine
×
Clear all
NCT05740449
2024-06-21
HEM-iSMART A
Princess Maxima Center for Pediatric Oncology
Phase 1/2
Withdrawn